In a world where personalized and precision medicine is rapidly reshaping healthcare, one segment has emerged as a silent hero—protein therapeutics. Whether it’s insulin for diabetes, monoclonal antibodies for cancer, or enzyme replacements for rare diseases, protein-based therapies are fueling a biopharmaceutical boom—and investors are taking notice. According to a...